Results for tag: "Achondroplasia Drug"

The Achondroplasia Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. It is focused on treatments for Achondroplasia, a genetic disorder that affects bone growth and causes short stature. Common treatments for Achondroplasia include growth hormone therapy, physical therapy, and orthopedic surgery. In some cases, drugs such as bisphosphonates may be used to reduce the risk of fractures. The Achondroplasia Drug market is highly competitive, with many companies offering treatments for the disorder. Some of the major players in the market include Pfizer, Novartis, Eli Lilly, and Merck. Other companies such as Amgen, Biogen, and Genentech are also active in the market, offering treatments for Achondroplasia and other musculoskeletal disorders. Show Less Read more